Computerized Decision Support for Pulmonary Hypertension
(CTEPH-DETECT Trial)
Trial Summary
What is the purpose of this trial?
To address the knowledge gap that exists among providers resulting in underdiagnosis of chronic thromboembolic pulmonary hypertension (CTEPH), the investigators have devised this 400-patient single-center Quality Improvement Initiative in the form of a randomized controlled trial of an EPIC Best Practice Advisory (BPA) on-screen alert versus no notification to increase echocardiographic screening for CTEPH and the diagnosis of CTEPH in patients with prior pulmonary embolism (PE) and symptoms/signs suggestive of pulmonary hypertension or recent pulmonary testing suggesting unexplained respiratory symptoms at 3 months. Aim #1: To determine the impact of a Best Practice Advisory (BPA), using the EPIC Electronic Health Record computerized decision support (CDS) software, on echocardiographic screening for CTEPH in patient with prior PE and symptoms/signs suggestive of pulmonary hypertension or recent pulmonary testing suggesting unexplained respiratory symptoms. Aim #2: To determine the impact of an EPIC BPA on the diagnosis of CTEPH in patient with prior PE and symptoms/signs suggestive of pulmonary hypertension or recent pulmonary testing suggesting unexplained respiratory symptoms.
Research Team
Gregory Piazza, MD, MS
Principal Investigator
BWH
Eligibility Criteria
This trial is for adults who've had a pulmonary embolism, are experiencing symptoms like fatigue or chest pain, or have unexplained respiratory issues on tests. They haven't had an echocardiogram in the last 6 months and are seen at specific clinics.Inclusion Criteria
Treatment Details
Interventions
- On-screen computerized decision support alert (Behavioral)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brigham and Women's Hospital
Lead Sponsor
Dr. William Curry
Brigham and Women's Hospital
Chief Medical Officer
MD from Columbia University College of Physicians and Surgeons
Dr. Scott Schissel
Brigham and Women's Hospital
Chief Executive Officer since 2021
MD from Columbia University College of Physicians and Surgeons
Bayer
Industry Sponsor
Bill Anderson
Bayer
Chief Executive Officer since 2023
BSc in Chemical Engineering from the University of Texas, MSc in Chemical Engineering and Management from MIT
Michael Devoy
Bayer
Chief Medical Officer since 2014
MD, PhD